Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab

Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum

“…Here we report a parallel therapeutic response of metastatic melanoma and primary cutaneous carcinomas in a patient with XP treated with anti PD-1. A similar case of regression of melanoma lung metastases, multiple basal cell carcinomas and Bowen disease in a patient with XP type E using pembrolizumab has recently been reported by Hauschild et al 4 Recent publications have reported the efficacy of anti-PD-1 immunotherapy in nonmelanoma skin cancers ( Table 1). The effect of anti-PD-1 immunotherapy has been reported for squamous cell carcinoma of the head and neck 12 and anti-PD-1 immunotherapy has become a major treatment for squamous cell lung cancer.…”

“…To our knowledge, limited data have been reported on the use of immune checkpoint inhibitors such as programmed cell death-1 (PD-1) inhibitors in patients with XP. 4 Tumour cells expressing the programmed cell death-ligand 1 (PD-L1) inactivate the apoptosis signal received from T lymphocytes. PD-1 inhibitors restore the antitumoral activity of immune cells against tumour cells 5 and are effective in melanoma, nonsmall cell lung carcinoma, bladder cancer and renal cell carcinoma.…”

“…Treatment of skin carcinomas in a patient with XP is similar to that of treatment in other patients and may include surgery, chemotherapy and cautious radiotherapy. To our knowledge, limited data have been reported on the use of immune checkpoint inhibitors such as programmed cell death‐1 (PD‐1) inhibitors in patients with XP …”

Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death‐1 inhibitors: A review of the literature

“…In this case, a rapid complete response after only three cycles was evidenced. Other reported cases of pembrolizumab in XP include, first of all Hauschild et al () (LE 4 following Oxford CEBM Levels of Evidence) subsequently Salomon et al () (LE 4 following Oxford CEBM Levels of Evidence) and they demonstrated a parallel therapeutic response of metastatic melanoma and primary cutaneous carcinomas. About adverse events, the most frequent are fatigue, rash, diarrhea, nausea or abdominal pain, and dysthyroidism.…”

Pembrolizumab treatment of a patient with xeroderma pigmentosum with disseminated melanoma and multiple nonmelanoma skin cancers

“…report treatment of a 17‐year‐old patient with XP with metastatic melanoma and multiple nonmelanoma skin cancers (NMSC) using the programmed death‐ligand 1 (PD‐L1) inhibitor, pembrolizumab. Hauschild et al . previously reported the use of pembrolizumab in another patient with XP with metastatic melanoma and multiple NMSC.…”